Edgewise Therapeutics (NASDAQ: EWTX) CMO sells 16,358 shares in open market

Rhea-AI Filing Summary

Edgewise Therapeutics CMO Joanne M. Donovan reported selling common stock in open-market transactions. On March 27, 2026, she sold a total of 16,358 shares of Edgewise Therapeutics, Inc. common stock in two sales at an average price of about $30.98 per share.

After these transactions, she directly holds 9,597 shares of common stock. Footnotes explain the shares sold were accumulated through multiple purchases under the company’s 2021 Employee Stock Purchase Plan between May 2022 and November 2024, including 594 shares purchased on November 17, 2025. The sales occurred across individual trades priced between $30.49 and $31.68.

Insider Trade Summary 10b5-1

Net Seller: 16,358 shares ($506,735)

Net Sell 2 txns

Insider Donovan Joanne M.

Role CMO

Sold 16,358 shs ($507K)

Type	Security	Shares	Price	Value
Sale	Common Stock	9,623	$30.9778	$298K
Sale	Common Stock	6,735	$30.9778	$209K

Holdings After Transaction: Common Stock — 16,332 shares (Direct)

Footnotes (1)

1. The shares sold were acquired through multiple purchases under the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan on May 15, 2022 (1,392 shares), November 15, 2022 (1,406 shares), May 15, 2023 (1,451 shares), November 15, 2023 (1,751 shares), May 15, 2024 (1,803 shares), and November 15, 2024 (1,820 shares). The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.49 to $31.68, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Includes 594 shares purchased on November 17,2025 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.

Key Figures

Shares sold (first transaction): 9,623 shares Shares sold (second transaction): 6,735 shares Total shares sold: 16,358 shares +4 more

7 metrics

Shares sold (first transaction) 9,623 shares Common stock sale on March 27, 2026 at average $30.9778

Shares sold (second transaction) 6,735 shares Common stock sale on March 27, 2026 at average $30.9778

Total shares sold 16,358 shares Aggregate open-market sales by CMO on March 27, 2026

Average sale price $30.9778 per share Average of multiple trades between $30.49 and $31.68

Post-sale holdings 9,597 shares Common stock directly held after second sale

ESPP recent purchase 594 shares Purchased November 17, 2025 under 2021 Employee Stock Purchase Plan

Sale price range $30.49–$31.68 per share Range of individual trade prices noted in footnote

Key Terms

Employee Stock Purchase Plan, open-market sale, average price, Reporting Person, +1 more

5 terms

Employee Stock Purchase Plan financial

"purchased on November 17,2025 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

average price financial

"The price reported in column 4 is an average price."

Reporting Person regulatory

"The Reporting Person undertakes to provide the Issuer"

non-derivative financial

""transaction_type": "non-derivative""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Donovan Joanne M.

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/27/2026		S		9,623(1)	D	$30.9778(2)	16,332(3)	D
Common Stock	03/27/2026		S		6,735	D	$30.9778(2)	9,597	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares sold were acquired through multiple purchases under the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan on May 15, 2022 (1,392 shares), November 15, 2022 (1,406 shares), May 15, 2023 (1,451 shares), November 15, 2023 (1,751 shares), May 15, 2024 (1,803 shares), and November 15, 2024 (1,820 shares).

2. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.49 to $31.68, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Includes 594 shares purchased on November 17,2025 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.

Remarks:

	John R. Moore Attorney-in-Fact for Donovan Joanne M.	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Edgewise Therapeutics (EWTX) report for CMO Joanne Donovan?

Edgewise Therapeutics reported that CMO Joanne M. Donovan sold common stock in open-market transactions. On March 27, 2026, she executed two sales totaling 16,358 shares at an average price of about $30.98 per share, as disclosed in the Form 4 filing.

How many Edgewise Therapeutics (EWTX) shares did the CMO sell and at what prices?

Joanne M. Donovan sold 9,623 shares and 6,735 shares of Edgewise Therapeutics common stock, totaling 16,358 shares. The reported average price was $30.9778 per share, with individual trades executed in a price range from $30.49 to $31.68, according to the filing footnote.

How many Edgewise Therapeutics (EWTX) shares does the CMO hold after the reported sales?

Following the reported March 27, 2026 transactions, Joanne M. Donovan directly holds 9,597 shares of Edgewise Therapeutics common stock. This post-transaction holding figure is stated in the Form 4 for the second sale and represents her remaining direct ownership position after the net-share dispositions.

What is the origin of the Edgewise Therapeutics (EWTX) shares sold by the CMO?

The filing notes that the shares sold were accumulated through multiple purchases under the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Purchases occurred on several dates from May 2022 through November 2024, with an additional 594 shares bought on November 17, 2025 under the same plan.

Were the Edgewise Therapeutics (EWTX) insider sales executed in a single trade or multiple trades?

The sales were executed in multiple trades. The Form 4 explains that the reported average price reflects numerous individual transactions, with sale prices ranging from $30.49 to $31.68 per share. The reporting person offers to provide detailed per-trade information upon request to interested parties.

What type of transaction code is used for the Edgewise Therapeutics (EWTX) CMO’s share sales?

The transactions are coded as “S,” which the filing describes as a sale in an open market or private transaction. These are non-derivative transactions involving common stock, and the Form 4 characterizes them specifically as open-market sales rather than derivative exercises or gifts.